Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 65-68

  Burger Dr , R A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; Fallopian tube cancer; Ovarian cancer; Primary peritoneal cancer; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; GEMCITABINE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TREBANANIB; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; DISEASE FREE SURVIVAL; FEMALE; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR RECURRENCE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857393484     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr529     Document Type: Conference Paper

References (33)

1. Kerbel RS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 2005; 8: 269-271.
2. Goodheart MJ, Ritchie JM, Rose SL et al. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 2005; 11: 3733-3742.
3. Hollingsworth HC, Kohn EC, Steinberg SM et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995; 147: 33-41.
4. Raspollini MR, Amunni G, Villanucci A et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004; 14: 815-823.
5. Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997; 80: 98-106.
6. Gasparini G, Bonoldi E, Viale G et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996; 69: 205-211.
7. Siddiqui GK, Elmasry K, Wong Te Fong AC et al. Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur J Gynaecol Oncol 2010; 31: 156-159.
8. Smerdel MP, Waldstrom M, Brandslund I et al. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19: 578-584.
9. Alvarez AA, Krigman HR, Whitaker RS et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999; 5: 587-591.
10. Shen GH, Ghazizadeh M, Kawanami O et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000; 83: 196-203.
11. Duncan TJ, Al-Attar A, Rolland P et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 2008; 14: 3030-3035.
12. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J. Clin Oncol 2007; 25: 5165-5171.
13. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin Oncol 2007; 25: 5180-5186.
14. Ovarian cancer (including fallopian tube cancer and primary peritoneal cancer). In National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, v.2.2010 edition. 2010.
15. Burger RAB, Bookman MA, Walker JL et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010.
16. Burger RAB, Bookman MA, Monk BJ et al. Safety and subgroup efficacy analyses in GOG 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: a Gynecologic Oncology Group study. Ann Oncol 2010.
17. Burger RAB, Fleming GF, Bookman MA et al. Phase III trial of bevacizumab in the primary treatment of advanced ovarian, primary peritoneal or fallopian tube cancer: a GOG study. In 13th Biennial Meeting of the International Gynecologic Cancer Society, Prague, 2010.
18. Perren TS, Pfisterer J, Ledermann J et al. ICON7: a phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 2010.
19. fisterer JP, Swart AM, Ledermann J et al. ICON7: a phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnoses epithelial ovarian, primary peritoneal or fallopian tube cancer. In 13th Biennial Meeting of the International Gynecologic Cancer Society, Prague, 2010.
20. Stuart GC, Kitchener H, Bacon M et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011; 21: 750-755.
21. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-1649.
22. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
23. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
24. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
25. Aghajanian CAF, Rutherford T, Smith DA et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin 2011.
26. Casanovas O, Hicklin DJ, Bergers G et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
27. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
28. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest 2003; 112: 1134-1136.
29. Ledermann JAR, Hackshaw A, Kaye SB et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009; 5501.
30. Friedlander M, Hancock KC, Rischin D et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010.
31. Hirte HWV, Fleming GF, Sugimoto AK et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008.
32. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27: 5601-5606.
33. Karlan BYO, Hansen VL, Richardson GE et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol 2010.